



Xolair in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · ALLERGIC ASTHMA, CSU, CRSWNP, FOOD ALLERGY

The clinical situation

Xolair (omalizumab) is a subcutaneous anti-IgE monoclonal antibody FDA-approved for moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria (CSU), nasal polyps (CRSwNP), and food allergy (IgE-mediated). Manufactured by Novartis and Genentech. Dosing is weight-and-IgE-based for asthma, and fixed-dose for CSU, administered every 2 or 4 weeks. Pre-treatment workup confirms IgE level, allergen sensitisation, and baseline asthma/CSU severity per FDA labelling; anaphylaxis precautions apply.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your allergist, pulmonologist, dermatologist, or ENT documents indication, IgE/weight, prior therapies, and Xolair rationale.
- 2 Baseline screening.** Serum IgE, weight, vaccination status, and anaphylaxis-risk counselling documented per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dose calculation, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; first dose administered in-office under anaphylaxis observation.

Indicative economics

Reference US cash-pay range: USD 2,500–4,500 per Xolair dose (weight/IgE-based) (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Novartis/Genentech authorised distribution.

Documentation. Physician kit tailored to SFDA review, with anti-IgE class safety annex (anaphylaxis). **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each dosing cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Xolair × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/xolair-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team